Literature DB >> 16961291

Ursodeoxycholic acid in the treatment of intraheptic cholestasis of pregnancy.

Yuling Liu1, Fuyuan Qiao, Haiyi Liu, Dayan Liu.   

Abstract

In order to observe the effect of ursodeoxycholic acid (UDCA) in the treatment of intrahepatic cholestasis of pregnancy (ICP), 68 patients with ICP were equally divided into treatment group and control group at random. The patients in treatment group were administered with UDCA 300 mg three times every day and those in control group received a combination of 10% glucose, Vitamin C and Inosine. Itching scores, serum ALT and total bile acids (TBA) were measured before, during and after treatment. The results showed that as compared with those before treatment, itching scores, serum ALT and TBA were significantly reduced after treatment (P < 0.05). The occurrences of premature labor, fetal asphyxia and meconium staining in amniotic fluid were significantly lower in treatment group than in control group (P < 0.05). It was suggested that UDCA was an effective drug in the treatment of ICP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961291     DOI: 10.1007/bf02829573

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  5 in total

1.  Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy.

Authors:  J Palma; H Reyes; J Ribalta; J Iglesias; M C Gonzalez; I Hernandez; C Alvarez; C Molina; A M Danitz
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

2.  Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.

Authors:  J Palma; H Reyes; J Ribalta; I Hernández; L Sandoval; R Almuna; J Liepins; F Lira; M Sedano; O Silva; D Tohá; J J Silva
Journal:  J Hepatol       Date:  1997-12       Impact factor: 25.083

3.  Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta.

Authors:  M A Serrano; D Brites; M G Larena; M J Monte; M P Bravo; N Oliveira; J J Marin
Journal:  J Hepatol       Date:  1998-05       Impact factor: 25.083

Review 4.  Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

5.  Bile acids increase response and expression of human myometrial oxytocin receptor.

Authors:  Alfredo M Germain; Sumie Kato; Jorge A Carvajal; Guillermo J Valenzuela; Gloria L Valdes; Juan C Glasinovic
Journal:  Am J Obstet Gynecol       Date:  2003-08       Impact factor: 8.661

  5 in total
  8 in total

1.  Is It Necessary to Perform the Pharmacological Interventions for Intrahepatic Cholestasis of Pregnancy? A Bayesian Network Meta-Analysis.

Authors:  Yi Shen; Jie Zhou; Sheng Zhang; Xu-Lin Wang; Yu-Long Jia; Shu He; Yuan-Yuan Wang; Wen-Chao Li; Jian-Guo Shao; Xun Zhuang; Yuan-Lin Liu; Gang Qin
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

2.  Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial.

Authors:  Lucy C Chappell; Vinita Gurung; Paul T Seed; Jenny Chambers; Catherine Williamson; James G Thornton
Journal:  BMJ       Date:  2012-06-13

3.  Pharmacological interventions for treating intrahepatic cholestasis of pregnancy.

Authors:  Kate F Walker; Lucy C Chappell; William M Hague; Philippa Middleton; Jim G Thornton
Journal:  Cochrane Database Syst Rev       Date:  2020-07-27

Review 4.  Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).

Authors:  Xiang Kong; Yan Kong; Fangyuan Zhang; Tingting Wang; Jin Yan
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 5.  Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis.

Authors:  Yang Zhang; Linlin Lu; David W Victor; Yongning Xin; Shiying Xuan
Journal:  Hepat Mon       Date:  2016-07-23       Impact factor: 0.660

6.  Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study.

Authors:  Mingjuan Luo; Mengyang Tang; Feng Jiang; Yizhen Jia; Robert Kien Howe Chin; Wei Liang; Hu Cheng
Journal:  Gastroenterol Res Pract       Date:  2021-03-25       Impact factor: 2.260

7.  Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis.

Authors:  Caroline Ovadia; Jenna Sajous; Paul T Seed; Kajol Patel; Nicholas J Williamson; George Attilakos; Francesco Azzaroli; Yannick Bacq; Linoy Batsry; Kelsey Broom; Romana Brun-Furrer; Laura Bull; Jenny Chambers; Yue Cui; Min Ding; Peter H Dixon; Maria C Estiú; Fergus W Gardiner; Victoria Geenes; Monika Grymowicz; Berrin Günaydin; William M Hague; Christian Haslinger; Yayi Hu; Ugo Indraccolo; Alexander Juusela; Stefan C Kane; Ayse Kebapcilar; Levent Kebapcilar; Katherine Kohari; Jūratė Kondrackienė; Maria P H Koster; Richard H Lee; Xiaohua Liu; Anna Locatelli; Rocio I R Macias; Riza Madazli; Agata Majewska; Kasia Maksym; Jessica A Marathe; Adam Morton; Martijn A Oudijk; Deniz Öztekin; Michael J Peek; Andrew H Shennan; Rachel M Tribe; Valeria Tripodi; Naciye Türk Özterlemez; Tharni Vasavan; L F Audris Wong; Yoav Yinon; Qianwen Zhang; Keren Zloto; Hanns-Ulrich Marschall; Jim Thornton; Lucy C Chappell; Catherine Williamson
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-04-27

8.  Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.

Authors:  Lucy C Chappell; Jennifer L Bell; Anne Smith; Louise Linsell; Edmund Juszczak; Peter H Dixon; Jenny Chambers; Rachael Hunter; Jon Dorling; Catherine Williamson; Jim G Thornton
Journal:  Lancet       Date:  2019-08-01       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.